☆ 4.3 Letter

Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

HEMASPHERE (2022)

Get Full Text
Add to Collection

Journal

HEMASPHERE
Volume 6, Issue 5, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HS9.0000000000000712

Keywords

-

Categories

Hematology

Funding

  1. Janssen Research Development

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.